Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS
Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer
Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif. (AP) _ Alector Inc. (ALEC) on Tuesday reported a loss of $55.1 million in its second quarter.
Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients
Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN
As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)